ApprovalTrail

Drug · DIN 02438070

COSENTYX

SINGLE-USE PREFILLED SENSOREADY PEN

Yes: authorized and sold in Canada

Authorized, and the company reports that it sells it in Canada.

Status Marketed since April 10, 2015; first marketed April 10, 2015.
Drug Identification Number (DIN)
02438070
Company (DIN owner)
Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
Schedule
Schedule D; Prescription
Dosage form
Solution
Route
Subcutaneous
Therapeutic class (ATC)
Secukinumab L04AC10
Class
Human
Record last updated
September 21, 2026

Active ingredients

As listed in the Drug Product Database.

IngredientStrengthPer
SECUKINUMAB150 MGML

Notices of Compliance

Health Canada approvals that name this DIN.

  • May 17, 2024: NOC 33262Supplement to a New Drug Submission (SNDS) · New indication: COSENTYX is indicated for the treatment of adult patients with moderate to severe hidradenitis suppurativa (acne inversa) who have responded inadequately to conventional systemic hidradenitis suppurativa therapy.Splitting of the existing Drug Identification Number for the pre-filled pen and pre-filled syringe presentations.
  • February 27, 2015: NOC 16644New Drug Submission (NDS)

Other DINs named COSENTYX